{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:31:37Z","timestamp":1787581897540,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00440039"],"award-info":[{"award-number":["RS-2024-00440039"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2022-KH130305"],"award-info":[{"award-number":["RS-2022-KH130305"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-25459535"],"award-info":[{"award-number":["RS-2025-25459535"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2023-00278980"],"award-info":[{"award-number":["RS-2023-00278980"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-25396539"],"award-info":[{"award-number":["RS-2025-25396539"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jconrel.2026.115106","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:26:25Z","timestamp":1781713585000},"page":"115106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Normalized internalization predicts potency of carcinoembryonic antigen-related cell adhesion molecule 6-targeting antibody\u2013drug conjugates"],"prefix":"10.1016","volume":"396","author":[{"given":"Joo-Young","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seul-Gi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Ho","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Hyun","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyeon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115106_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115106_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115106_bb0015","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115106_bb0020","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_431766","article-title":"Unlocking the potential: biomarkers of response to antibody-drug conjugates","volume":"44","author":"Ascione","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.jconrel.2026.115106_bb0025","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved tumor penetration and single-cell targeting of antibody-drug conjugates increases anticancer efficacy and host survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0030","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","article-title":"Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors","volume":"71","author":"Rudnick","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0035","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00262-008-0518-1","article-title":"Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability","volume":"57","author":"Schmidt","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2026.115106_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of antibody-drug conjugates in cancer cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0045","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acs.bioconjchem.7b00013","article-title":"Improved lysosomal trafficking can modulate the potency of antibody drug conjugates","volume":"28","author":"DeVay","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.115106_bb0050","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.081626898","article-title":"Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors","volume":"98","author":"Pluen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115106_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)-a necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2026.115106_bb0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115106_bb0065","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.tips.2021.07.005","article-title":"Key metrics to expanding the pipeline of successful antibody-drug conjugates","volume":"42","author":"Nessler","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.115106_bb0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.bbrc.2004.03.128","article-title":"CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma","volume":"317","author":"Duxbury","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115106_bb0075","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41467-024-46167-1","article-title":"Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models","volume":"15","author":"Nakazawa","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115106_bb0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and dissemination precede pancreatic tumor formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115106_bb0085","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115106_bb0090","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/ncomms2406","article-title":"In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels","volume":"4","author":"Sekine","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115106_bb0095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jcp.20887","article-title":"GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction","volume":"210","author":"Ordonez","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2026.115106_bb0100","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1534-5807(02)00145-4","article-title":"GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway","volume":"2","author":"Sabharanjak","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jconrel.2026.115106_bb0105","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1038\/s41467-024-53746-9","article-title":"Structural insights into epitope-paratope interactions of a monoclonal antibody targeting CEACAM5-expressing tumors","volume":"15","author":"Kumar","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115106_bb0110","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11523-025-01154-4","article-title":"A phase I study of the anti-CEACAM6 antibody tinurilimab (BAY 1834942) in patients with advanced solid tumors","volume":"20","author":"Siu","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jconrel.2026.115106_bb0115","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1369\/0022155415603768","article-title":"Expression of carcinoembryonic cell adhesion molecule 6 and alveolar epithelial cell markers in lungs of human infants with chronic lung disease","volume":"63","author":"Gonzales","year":"2015","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.jconrel.2026.115106_bb0120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1158\/1535-7163.MCT-24-0444","article-title":"Broad-Spectrum efficacy of CEACAM6-targeted antibody-drug conjugate with BET protein degrader in colorectal, lung, and breast Cancer mouse models","volume":"24","author":"Kogai","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115106_bb0125","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1208\/s12248-015-9766-0","article-title":"Antibody drug conjugates: application of quantitative pharmacology in modality design and target selection","volume":"17","author":"Sadekar","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.115106_bb0130","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","article-title":"Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18632\/oncoscience.435","article-title":"Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules?","volume":"5","author":"Nessler","year":"2018","journal-title":"Oncoscience"},{"key":"10.1016\/j.jconrel.2026.115106_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202401016","article-title":"Novel FRET-based immunological synapse biosensor for the prediction of chimeric antigen receptor-T cell function","volume":"9","author":"Lee","year":"2025","journal-title":"Small Methods"},{"key":"10.1016\/j.jconrel.2026.115106_bb0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12943-022-01574-0","article-title":"Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8(+) T cells for cancer immunotherapy","volume":"21","author":"Jung","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115106_bb0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cac2.12497","article-title":"Harnessing SARS-CoV-2-specific CD8(+) T cells to kill target tumor cells for cancer immunotherapy","volume":"44","author":"Jung","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.jconrel.2026.115106_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113727","article-title":"Engineering IgG antibodies for intracellular targeting and drug delivery","volume":"382","author":"Kim","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115106_bb0160","doi-asserted-by":"crossref","first-page":"eaay2174","DOI":"10.1126\/sciadv.aay2174","article-title":"Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth","volume":"6","author":"Shin","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115106_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.134668","article-title":"Enhancing the cytotoxicity of immunotoxins by facilitating their dissociation from target receptors under the reducing conditions of the endocytic pathway","volume":"278","author":"Lee","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2026.115106_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190982","article-title":"Characterization of the naive murine antibody repertoire using unamplified high-throughput sequencing","volume":"13","author":"Rettig","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.115106_bb0175","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2008110","article-title":"T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction","volume":"11","author":"Pinkert","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.115106_bb0180","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1158\/0008-5472.CAN-05-0420","article-title":"Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)","volume":"65","author":"Blumenthal","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0185","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/dmd.119.089276","article-title":"Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells","volume":"48","author":"Sharma","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2026.115106_bb0190","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-12-1173","article-title":"DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma","volume":"12","author":"Li","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115106_bb0195","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0200","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-09-0586","article-title":"CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates","volume":"15","author":"Govindan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0205","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/1535-7163.MCT-23-0437","article-title":"Improving intracellular delivery of an antibody-drug conjugate targeting carcinoembryonic antigen increases efficacy at clinically relevant doses in vivo","volume":"23","author":"Nessler","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115106_bb0225","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1038\/s41467-020-19498-y","article-title":"Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates","volume":"11","author":"Lu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115106_bb0230","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1208\/s12248-016-9892-3","article-title":"Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design","volume":"18","author":"Maass","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.115106_bb0235","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115106_bb0240","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115106_bb0245","first-page":"4776","article-title":"An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a \u201cbinding site barrier\u201d","volume":"51","author":"van Osdol","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0250","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2407-7-2","article-title":"Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers","volume":"7","author":"Blumenthal","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2026.115106_bb0255","doi-asserted-by":"crossref","first-page":"18347","DOI":"10.1038\/s41598-019-54545-9","article-title":"Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in pancreatic ductal adenocarcinoma (PDA): an integrative analysis of a novel therapeutic target","volume":"9","author":"Pandey","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115106_bb0260","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2174\/0115680096260614231115192343","article-title":"CT109-SN-38, a novel antibody-drug conjugate with dual specificity for CEACAM5 and 6, elicits potent killing of pancreatic cancer cells","volume":"24","author":"Cardenas","year":"2024","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jconrel.2026.115106_bb0265","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0270","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/1535-7163.MCT-14-0798","article-title":"High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates","volume":"14","author":"de Goeij","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115106_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/biom15101477","article-title":"Bispecific antibody and antibody-drug conjugate as novel candidates for treating pancreatic ductal adenocarcinoma","volume":"15","author":"Seo","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2026.115106_bb0280","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/2767-9764.CRC-23-0284","article-title":"Tusamitamab Ravtansine in patients with advanced solid tumors: phase I study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens","volume":"3","author":"Tabernero","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115106_bb0285","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2026.115106_bb0290","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1038\/s41591-025-03843-z","article-title":"Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115106_bb0295","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14712598.2020.1696767","article-title":"Rationale, discovery and clinical development of NEO-201","volume":"20","author":"Arlen","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.115106_bb0300","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/2212697X02666150602215823","article-title":"Emerging role and targeting of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in human malignancies","volume":"2","author":"Johnson","year":"2015","journal-title":"Clin. Cancer Drugs"},{"key":"10.1016\/j.jconrel.2026.115106_bb0305","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41589-019-0342-2","article-title":"CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity","volume":"15","author":"Tsui","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.115106_bb0310","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/0008-5472.CAN-11-3925","article-title":"Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors","volume":"72","author":"Pak","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115106_bb0315","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"Rios-Luci","year":"2017","journal-title":"Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:42:00Z","timestamp":1787578920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"alternative-id":["S0168365926005092"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115106","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Normalized internalization predicts potency of carcinoembryonic antigen-related cell adhesion molecule 6-targeting antibody\u2013drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115106"}}